Centre d'Affaires Poincaré, Rue Poincaré, Nice, France.
Oral Dis. 2012 Oct;18(7):633-8. doi: 10.1111/j.1601-0825.2012.01918.x. Epub 2012 Mar 15.
Antitumour necrosis factor (TNF-α) therapy has a potential to benefit patients with oral lesions of Crohn's disease (CD) and patients with orofacial granulomatosis (OFG). The most appropriate use would appear to be in patients with severe or multisystem features, where other available agents have failed or have been associated with adverse effects. TNF-α antagonists (infliximab in particular) have a role in the management of orofacial CD and OFG, but potential adverse effects of TNF-α antagonists include acute infusion reactions, infection and increased risk of malignancy. Thus, a full risk-benefit analysis is indicated, with patient selection, use and subsequent monitoring coordinated with gastroenterologists with appropriate training and experience in biological therapies.
抗肿瘤坏死因子（TNF-α）治疗有可能使患有克罗恩病（CD）口腔病变和口腔肉芽肿病（OFG）的患者受益。最适合的应用似乎是在有严重或多系统特征的患者中，其他可用的药物已经失败或与不良反应相关。TNF-α拮抗剂（特别是英夫利昔单抗）在口腔 CD 和 OFG 的治疗中有一定作用，但 TNF-α拮抗剂的潜在不良反应包括急性输注反应、感染和恶性肿瘤风险增加。因此，需要进行全面的风险效益分析，选择患者、使用和后续监测需要与具有生物治疗适当培训和经验的胃肠病学家协调。
